Despite demonstration of anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature. The gene discussed is THBS2; the disease is Crouzon syndrome-acanthosis nigricans syndrome.